News articles about Immune Pharmaceuticals (NASDAQ:IMNP) have been trending somewhat negative recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immune Pharmaceuticals earned a media sentiment score of 0.00 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.6469913410248 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of research firms have commented on IMNP. ValuEngine upgraded shares of Immune Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Maxim Group started coverage on shares of Immune Pharmaceuticals in a research report on Friday, January 5th. They set a “buy” rating and a $3.00 target price on the stock.
Shares of Immune Pharmaceuticals (NASDAQ IMNP) traded down $0.01 during mid-day trading on Wednesday, hitting $0.53. 837,500 shares of the stock were exchanged, compared to its average volume of 2,319,548. Immune Pharmaceuticals has a 12 month low of $0.40 and a 12 month high of $5.02. The firm has a market capitalization of $9.67, a price-to-earnings ratio of -0.13 and a beta of 1.50. The company has a debt-to-equity ratio of 3.04, a current ratio of 0.03 and a quick ratio of 0.03.
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.